Klaria changes the date of publication for its Q3 interim report to November 15

Today, Klaria Pharma Holding AB announces that company’s interim report for the third quarter of 2019 will be released on November 15. This change is due to the ongoing fusion process with Karessa Pharma Holding AB as announced on November 5, 2019.

The original publication date for the interim report was November 28. Klaria’s updated financial calendar is available on the company’s website.

For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Scott Boyer, CEO Klaria Pharma Holding AB (publ)
scott.boyer@klaria.com
Tel: +46 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.